• All
  • Important
  • Financial Update
  • Fund Raise
  • Board Meeting
  • Dividend/Bonus
  • JV/Acquisition
  • Investor Meet
  • Insider Trade
  • Pledging
  • Others
    ALPHA TRIBE

    Ajanta Pharma Limited — Board Meeting, 30-01-2026: Outcome of Board Meeting

    30-01-2026 | 03:03 pm

    Ajanta Pharma's board approved strong Q3 financial results. Consolidated revenue surged 20% to ₹1,375 Cr, with PAT up 18% to ₹274 Cr. India branded generics outperformed the market, while US generics revenue jumped 52%. Solid growth continues!

    No comments yet. Be the first to comment!

    All announcements from Ajanta Pharma Limited